Max Chat
Company Analysis OncoTherapy Science, Inc.
1. Summary
Advantages
- Price (21 Β₯) is less than fair price (39.12 Β₯)
Disadvantages
- Dividends (0%) are below the sector average (2.86%).
- The stock's return over the last year (-58.82%) is lower than the sector average (0%).
- Current debt level 12.32% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-213.12%) is lower than the sector average (ROE=1.13%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| OncoTherapy Science, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 0% | 0.1% |
| 90 days | -12.5% | 6.1% | 25.6% |
| 1 year | -58.8% | 0% | -4.8% |
4564 vs Sector: OncoTherapy Science, Inc. has significantly underperformed the "Healthcare" sector by -58.82% over the past year.
4564 vs Market: OncoTherapy Science, Inc. has significantly underperformed the market by -54.02% over the past year.
Stable price: 4564 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 4564 with weekly volatility of -1.13% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (21 Β₯) is lower than the fair price (39.12 Β₯).
Price significantly below the fair price: The current price (21 Β₯) is 86.3% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (112.41).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (150.15).
4.3. P/BV
P/BV vs Sector: The company's P/BV (12.63) is lower than that of the sector as a whole (70.29).
P/BV vs Market: The company's P/BV (12.63) is lower than that of the market as a whole (120.08).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (7.32) is lower than that of the sector as a whole (75.54).
P/S vs Market: The company's P/S indicator (7.32) is lower than that of the market as a whole (120.98).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-3.15) is lower than that of the sector as a whole (29.32).
EV/Ebitda vs Market: The company's EV/Ebitda (-3.15) is lower than that of the market as a whole (120.75).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -8.5% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-8.5%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1.61%).
5.4. ROE
ROE vs Sector: The company's ROE (-213.12%) is lower than that of the sector as a whole (1.13%).
ROE vs Market: The company's ROE (-213.12%) is lower than that of the market as a whole (9.39%).
5.5. ROA
ROA vs Sector: The company's ROA (-108.31%) is lower than that of the sector as a whole (0.6587%).
ROA vs Market: The company's ROA (-108.31%) is lower than that of the market as a whole (4.46%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (9.07%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (8.83%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '2.86%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
